Ser342
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser342  -  CCR5 (human)

Site Information
AssVyTRstGEQEIs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449902

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , electrophoretic mobility shift ( 3 ) , flow cytometry ( 2 ) , mutation of modification site ( 1 , 2 , 3 ) , phosphoamino acid analysis ( 3 )
Disease tissue studied:
lymphoma ( 2 ) , anaplastic large cell lymphoma ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
GRK3 (human) ( 3 )
Treatments:
AOP-RANTES ( 3 ) , CCL3 ( 2 ) , RANTES ( 3 )

Downstream Regulation
Effects of modification on CCR5:
molecular association, regulation ( 1 ) , receptor desensitization, altered ( 3 ) , receptor internalization, altered ( 1 , 2 , 3 )
Induce interaction with:
ARRB1 (rat) ( 1 ) , ARRB2 (rat) ( 1 )

References 

1

Huttenrauch F, et al. (2002) Beta-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif. J Biol Chem 277, 30769-77
12065593   Curated Info

2

Brandt SM, et al. (2002) Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem 277, 17291-9
11782464   Curated Info

3

Oppermann M, Mack M, Proudfoot AE, Olbrich H (1999) Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J Biol Chem 274, 8875-85
10085131   Curated Info